TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2023-09-19
施金元SHIH, JIN-YUAN
- 計畫主持人
- 執行臨床試驗年資 17 年 9 個月
發表文獻
41筆
21
Wu, C. W., Yang, C. Y., Chang, Y. L., & Shih, J. Y. (2020). Successful Management of a ROS1-Rearranged Pulmonary Pleomorphic Carcinoma Using Serial Tyrosine Kinase Inhibitors. Oncotargets and Therapy, 13, 10123-10127. https://doi.org/10.2147/ott.S262653
22
Wu, S. G., Chiang, C. L., Liu, C. Y., Wang, C. C., Su, P. L., Hsia, T. C., Shih, J. Y., & Chang, G. C. (2020). An Observational Study of AcquiredEGFRT790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan. Frontiers in Oncology, 10, Article 1481. https://doi.org/10.3389/fonc.2020.01481
23
Wu, S. G., Yu, C. J., Yang, J. C. H., & Shih, J. Y. (2020). The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation. Therapeutic Advances in Medical Oncology, 12, Article 1758835920946156. https://doi.org/10.1177/1758835920946156
24
Yang, C. Y., Liao, W. Y., Ho, C. C., Chen, K. Y., Tsai, T. H., Hsu, C. L., Liu, Y. N., Su, K. Y., Chang, Y. L., Wu, C. T., Liao, B. C., Hsu, C. C., Hsu, W. H., Lee, J. H., Lin, C. C., Shih, J. Y., Yang, J. C. H., & Yu, C. J. (2020). Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib. Oncologist, 25(8), 702-711. https://doi.org/10.1634/theoncologist.2020-0088
25
Yang, C. Y., Liao, W. Y., Ho, C. C., Chen, K. Y., Tsai, T. H., Hsu, C. L., Su, K. Y., Chang, Y. L., Wu, C. T., Hsu, C. C., Liao, B. C., Hsu, W. H., Lee, J. H., Lin, C. C., Shih, J. Y., Yang, J. C. H., & Yu, C. J. (2020). Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors. European Journal of Cancer, 124, 110-122. https://doi.org/10.1016/j.ejca.2019.10.019
26
Chang, L. C., Lim, C. K., Chang, L. Y., Chen, K. Y., Shih, J. Y., & Yu, C. J. (2019). Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors. European Journal of Cancer, 119, 77-86. https://doi.org/10.1016/j.ejca.2019.06.025
27
Chen, L., & Yang, C. (2019). Case Report: A Rare Epidermal Growth Factor Receptor (EGFR) H773L/V774M Compound Mutation in Advanced Non-Small Cell Lung Cancer with Poor Response to EGFR Tyrosine Kinase Inhibitor. American Journal of Respiratory and Critical Care Medicine, 199. ://WOS:000466776704468
28
Chen, Y. H., Chen, Y. F., Chen, C. Y., Shih, J. Y., & Yu, C. J. (2019). Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study. Bmc Cancer, 19(1), Article 1006. https://doi.org/10.1186/s12885-019-6140-0
29
Gow, C. H., Hsieh, M. S., Lin, Y. T., Liu, Y. N., & Shih, J. Y. (2019). Validation of Immunohistochemistry for the Detection of BRAF V600E-Mutated Lung Adenocarcinomas. Cancers, 11(6), Article 866. https://doi.org/10.3390/cancers11060866
30
Lee, J. H., Chen, H. Y., Hsu, F. M., Chen, J. S., Liao, W. Y., Shih, J. Y., Yu, C. J., Chen, K. Y., Tsai, T. H., & Yang, J. C. H. (2019). Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors. Oncologist, 24(12), E1417-E1425. https://doi.org/10.1634/theoncologist.2019-0152
